Cytokinetics Q3 net loss $142.3M, cash $896M; FDA AdCom Dec 13 for omecamtiv mecarbil

CYTOKINETICS INC

2022-Q3 EPS reported -$2.85 revenue$92,631,000

Net loss of $142.3M ($1.52/share) vs $76.1M ($0.95) in Q3 2021; revenue $2.5M, down from $5.4M.
Cash, equivalents and investments $896.2M; net proceeds of $523.6M from 3.50% convertible notes due 2027.
FDA Advisory Committee to review omecamtiv mecarbil NDA on Dec 13, 2022; PDUFA target Feb 28, 2023.
SEQUOIA-HCM (aficamten Phase 3) enrollment ongoing; results expected in 2H 2023.
COURAGE-ALS (reldesemtiv Phase 3) continues after first interim analysis; enrollment to complete 1H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYTOKINETICS INC reported third quarter of 2022 results: net income Net loss for the third quarter was $142.3 million, EPS $1.52 per share.

Period: third quarter of 2022
Net income: Net loss for the third quarter was $142.3 million
EPS: $1.52 per share
Result: reported results

Exact text from the filing

Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2022. Net loss for the third quarter was $142.3 million, or $1.52 per share

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-021847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.